About: Osteonecrosis secondary to antiphospholipid syndrome: a case report, review of the literature, and treatment strategy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Osteonecrosis secondary to antiphospholipid syndrome: a case report, review of the literature, and treatment strategy Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 12 December 2009

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2009 (ast) наукова стаття, опублікована в грудні 2009 (uk) scientific article published on 12 December 2009 (en) 2009 թվականի դեկտեմբերի 12-ին հրատարակված գիտական հոդված (hy) مقالة علمية نشرت في 12 ديسمبر 2009 (ar)
publication date	wds:Q37655516-EC1C7D4B-65E4-4C58-8B8E-CD5ABEE79374
publication date	2009-12-12 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37655516-094CDAE4-D1E7-418D-9961-AC454F3ACF50
language of work or name	English
exact match	wds:Q37655516-62E48AE7-1C1C-44FD-B7B7-7C14F01DBC41
exact match	https://scigraph.springernature.com/pub.10.1007/s00296-009-1269-9
cites work	wds:Q37655516-0140A2A8-7A26-4267-B90B-D2C4580139F9 wds:Q37655516-0B3ACFA9-4B8E-464D-8565-01671453260E wds:Q37655516-0E62E2F6-D474-4E37-BF95-BA26EA5D1827 wds:Q37655516-0F083EE5-92BA-43B4-9D3B-DE4BB21D717B wds:Q37655516-1B902BDC-1649-423B-8885-B05A304574CF wds:Q37655516-34DE4C35-5E09-4A26-9B95-ED99E968CAB5 wds:Q37655516-3504C5B3-9719-4609-AE19-EB25A265E036 wds:Q37655516-38F44E23-82EA-4211-9FC9-386645FE0A91 wds:Q37655516-3D0A6ABD-B415-4867-ADC7-3E659EA97BF8 wds:Q37655516-3DCE0845-910E-4264-837E-91B946CB93FC wds:Q37655516-3E0A7801-5AF1-41BB-AE7B-25D1ED1F8B38 wds:Q37655516-43CD38F2-D3BA-4407-A635-1039FB5C91D8 wds:Q37655516-5A66EE7A-B460-43D5-84F9-E0FABF0A1DC9 wds:Q37655516-5FFF10D4-3D4F-4FF2-A574-3FB9051548FF wds:Q37655516-6A0E9239-D677-41FE-9CD8-E0E617F12E97 wds:Q37655516-6BFA0739-F11E-4948-BD72-BF48866D52AD wds:Q37655516-6E14AAC6-FE81-4746-A396-5CA470F19D86 wds:Q37655516-71473E64-586C-4A0B-A089-A1C9698BEC9F wds:Q37655516-718EDC0F-45EF-4E67-A801-219C28EF7661 wds:Q37655516-73289363-A96D-4B93-8281-E8FA05854D0A wds:Q37655516-7343D929-C7A4-44E0-ADE1-5992F74AE13D wds:Q37655516-7EEEFA7F-ABDC-4248-8322-E0BBFB929B35 wds:Q37655516-80A21538-7F19-4FE1-8004-10FCCCD46AC1 wds:Q37655516-814E6D94-DFB7-48F3-AED2-ADAADBAD7AD4 wds:Q37655516-8319F87A-E755-418F-BD95-BF3757CCCF22 wds:Q37655516-84300CD3-56AF-4128-9CF2-CCD6BF6613C0 wds:Q37655516-9166F8AA-EF40-4DA1-9CD9-3F1814C0802D wds:Q37655516-9C168967-1D52-4AB2-9F87-74E3339746C7 wds:Q37655516-9D66C11C-C548-441D-9BA6-A21418BC1789 wds:Q37655516-B40F962B-A25D-42D5-B579-437BF062C380 wds:Q37655516-B6E0677C-BE31-4C4B-BF3A-94AB58717BD7 wds:Q37655516-BF2C60B5-CAA1-4285-AA49-817A63B4E14D wds:Q37655516-C46F4C37-E36D-46F7-AA24-5A8C769756EF wds:Q37655516-C5CE5E64-9C29-4485-A64B-E5738578C27F wds:Q37655516-CAB406FA-71BF-4609-96F9-0848C7493D1F wds:Q37655516-D8AF0234-3D41-4F8F-A357-8EE03969D335 wds:Q37655516-DEE385CD-7BE0-4C16-81D3-30BEC4C722DB wds:Q37655516-E30C1588-BC74-4429-9B01-EEDE202EDE52 wds:Q37655516-EC6B0D9C-C09E-4528-A47B-C01A46BBAB4F wds:Q37655516-F996EBC2-103B-4C31-91B1-9F16578D5CAD
cites work	Antiphospholipid syndrome treated with prednisolone, cyclophosphamide and double-filtration plasmapheresis. Procoagulants and osteonecrosis Hypofibrinolysis: a common, major cause of osteonecrosis International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) Endothelial cells as target for antiphospholipid antibodies. Human Polyclonal and Monoclonal Anti-β2-Glycoprotein I Antibodies React In Vitro with Endothelial Cells Through Adherent β2-Glycoprotein I and Induce Endothelial Activation The "primary" antiphospholipid syndrome: major clinical and serological features. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Aseptic necrosis of bone in systemic lupus erythematosus. Relationship to corticosteroid therapy Avascular osteonecrosis in patients with SLE: relation to corticosteroid therapy and anticardiolipin antibodies Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes Avascular necrosis of bone in systemic lupus erythematosus: possible role of haemostatic abnormalities Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies The antiphospholipid and thrombosis syndromes Protein C and S deficiency, thrombophilia, and hypofibrinolysis: pathophysiologic causes of Legg-Perthes disease Rituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation Activation of cultured vascular endothelial cells by antiphospholipid antibodies. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Role of thrombotic and fibrinolytic alterations in the pathogenesis and treatment of osteonecrosis Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study Risk factors for osteonecrosis in systemic lupus erythematosus Avascular necrosis of bone and antiphospholipid antibodies in systemic lupus erythematosus Beta2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant Anticardiolipin antibodies and thrombosis Computer analysis of factors influencing the appearance of aseptic necrosis in patients with SLE Plasma from systemic lupus erythematosus patients with antiphospholipid antibodies promotes platelet aggregation. Studies in a perfusion system The pathophysiology of alveolar osteonecrosis of the jaw: anticardiolipin antibodies, thrombophilia, and hypofibrinolysis Thyropathic endemic dystrophy in an area of the Argeş Valley Avascular necrosis associated with anticardiolipin antibodies Antiphospholipid antibodies and thrombosis. A consequence, coincidence, or cause?

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 176 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software